Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on TG Therapeutics and keeping the price target at $60.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Emily Bodnar’s rating is based on TG Therapeutics’ strong financial performance and strategic initiatives. The company reported Briumvi revenues that slightly exceeded both consensus and internal estimates, demonstrating a 10% quarter-over-quarter growth. Additionally, TG Therapeutics increased its 2025 US revenue guidance to $585 million, reflecting confidence in continued growth.
The company has also shown effective execution in its marketing strategies, such as the national digital campaign, which has positively impacted brand awareness and patient engagement. Furthermore, clinical trial data from the ENABLE Phase 4 trial indicate favorable outcomes, supporting Briumvi’s competitive position in the market. The ongoing ENHANCE trial, with its quick enrollment, suggests strong demand for the drug’s new dosing regimen, which could further enhance its market appeal. These factors collectively contribute to a positive outlook for TG Therapeutics, justifying the Buy rating.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 5.9% and a 37.02% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Arcus Biosciences, and Olema Pharmaceuticals.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.